Fire bug Velafax

No clinically significant interaction of venlafaxine with antihypertensive (including beta-blockers, ACE inhibitors and diuretics) and hypoglycemic drugs.

Influence on the ability to drive vehicles and control mechanisms. Venlafaxine has virtually no effect on psychomotor and cognitive functions. However, given the possibility of significant effects in the central nervous system, during treatment with venlafaxine, care must be taken when driving vehicles and engaging in an environment that requires an increased concentration of attention and speed of psychomotor reactions..

From the side of metabolism: often - increase in serum cholesterol (especially after prolonged use in the high doses), decreasing or increasing in body weight; infrequently - hyponatremia, syndrome of insufficient secretion of ADH; in some cases - increased levels of prolactin in blood plasma.

Venlafaxine can affect the pharmacodynamics of other drugs that the serotonergic neurotransmitter system, so caution should be exercised when it is prescribed with triptans, other SSRIs and lithium preparations..

Symptoms: ECG changes, sinus or ventricular tachycardia, bradycardia, hypotension, convulsive states, depression of consciousness, especially with an overdose of venlafaxine in combination with alcohol or other psychotropic drugs.

The antidepressant effect of venlafaxine is associated with increased neurotransmitter activity in the central nervous system. Venlafaxine and its main metabolite, O-desmethylvenlafaxine (EFA), are potent inhibitors of serotonin and norepinephrine reuptake and weakly inhibit dopamine reuptake by neurons. Venlafaxine and EFA effectively effect the reuptake of neurotransmitters. Venlafaxine and EFA have beta-blocking properties.

In renal and hepatic insufficiency, special care is required. In some cases, a dose reduction is required (see "Method of administration and dose").

An antidepressant that does not chemically belong to any class of antidepressants (tricyclic, tetracyclic or others) is a racemate of two active enantomers. The mechanism of the antidepressant effect of the drug is associated with its ability to potentiate the transmission of a central nervous system. Venlafaxine and its main metabolite, O-desmethylvenlafaxine (EFA), are potent serotonin and noradrenaline reuptake inhibitors and weaker dopamine reuptake inhibitors. In addition, venlafaxine and EFA reduce beta-adrenergic reactivity both after single injection, and with constant use. Venlafaxine does not have affinity for m-cholinergic, histamine H receptors and α 1 brain adrenergic receptors. Does not inhibit MAO activity. The drug does not affect the release of norepinephrine from the brain tissue..

The use of venlafaxine may be associated with the development of psychomotor anxiety, which is clinically reminiscent of akathisia and is characterized by subjectively unpleasant and distressing anxiety with the need to move, often combined with the inability to sit or stand still. This condition is most often observed during the first few weeks of treatment. If such symptoms occur, increasing the dose may have an adverse effect, and the appropriateness of continuing venlafaxine should be considered..

Usprkos tome, u pojedinim slučajevima liječnik može propisati Velafax XL kapsule osobi mlađoj od 18 godina, ako je to iz drugih razloga opravdano. Ako je Vaš liječnik odredio liječenje Velafax XL kapsulama osobi mlađoj od 18 godina, zatražite od liječnika da Vam detaljno obrazloži svoju odluku i pitajte sve što Vas zanima i brine u vezi tim.

Ako Vam se jave misli o samoubojstvu ili samoozljeđivanju, odmah o tome obavijestite svog liječnika ili otiđite u najbližu bolnicu.

Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Velafax in the following countries:

Important Notice: The International Drugs.com database is in BETA release. This means it is still under development and may contain inaccuracies. It is a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to be appropriate or appropriate for you. Consult with your healthcare professional.

Przed zastosowaniem leku należy sprawdzić datę ważności podaną na opakowaniu (etykiecie). Nie należy stosować leku po terminie ważności. Przechowuj lek w szczelnie zamkniętym opakowaniu, w miejscu niedostępnym i niewidocznym dla dzieci, zgodnie z wymogami producenta.

Bardzo często: zaparcia, nudności, ból głowy, zawroty głowy, suchość Blony śluzowej jamy ustnej, bezsenność, nerwowość, zaburzenia ejakulacji lub orgazmu, pocenie pot często: nadciśnienie, kołatanie serca, rozszerzenie naczyń, anoreksja, biegunka, niestrawność, wymioty, Bole brzucha , dreszcze, gorączka, zwiększenie stężenia cholesterolu we krwi, zwiększenie lub zmniejszenie masy ciała, Bole Stawów, Bole mięśni, niezwykłe sny, pobudzenie, Lek, splątanie, zwiększenie napięcia mięśniowego, zaburzenia czucia, drżenia, częste oddawanie moczu, zmniejszenie libido, impotencja, zaburzenia cyklu miesiączkowego, duszność, ziewanie, świąd, wysypka skórna, zaburzenia widzenia (zaburzenia akomodacji, rozszerzenie źrenic), szumy uszne.

Gdy przyjmujesz inne leki działające na ośrodkowy układ nerwowy (leki nasenne, uspakajające, przeciwdepresyjne, przeciwdrgawkowe), cymetydynę, leki przeciwzrzz Ponadto należy poinformować lekarza o wszystkich przyjmowanych lekach nawet tych dostępnych bez recepty.

Important Notice: The International Drugs.com database is in BETA release. This means it is still under development and may contain inaccuracies. It is a substitute for the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to be appropriate or appropriate for you. Consult with your healthcare professional.

Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Velafax in the following countries:

With simultaneous use of diazepam, the pharmacokinetics of drugs and their metabolites does not significantly change.

Velafax (venlafaxine) is a drug of the antidepressant group. Promotes the propagation of electrical signals along the axis of the nervous system. Supports the neuronal uptake of 5-hydroxytryptamine and norepinephrine, to a small extent, dopamine. Reduces the sensitivity of beta-adrenergic receptors. Does not interact with acetylcholine m-receptors, histamine H1 receptors, cerebral alpha-1-adrenergic receptors. Does not reduce the activity of the enzyme monoamine oxidase. It does not affect the release of norepinephrine by the brain. Quickly and fully absorbed in the gastrointestinal tract. Peak concentration occurs approximately 2-3 hours after administration. The presence in the gastrointestinal tract of food contents pushes the moment of reaching the peak concentration of the active substance in the blood for 20-30 minutes. Undergoes intensive metabolic transformations in the liver. It is used for depression of various origins, including Depression against anxiety disorder. The optimal time for taking drugs with food. It is recommended to maintain equal time intervals between doses. Multiplicity of application - 2 times a day. The dose is determined according to the clinical situation. After the treatment has been performed, the dose may be reduced to a minimum level that provides the desired pharmacological effect. Supportive care at the same time. Elderly people take Velafax on a general basis, dose reduction is not required, however, when prescribing the drug to patients of this age group.

With caution, the drug should be prescribed in case of impaired liver or kidney function. Sometimes a dose reduction may be required..

Patients, especially the elderly, should be warned about the possibility of dizziness and impaired sense of balance (orthostatic hypotension).

The use of venlafaxine may be associated with the development of psychomotor anxiety, which is clinically reminiscent of akathisia and is characterized by subjectively unpleasant and distressing anxiety with the need to move, often combined with the inability to sit or stand still. This condition is most often observed during the first few weeks of treatment. If such symptoms occur, increasing the dose may have an adverse effect, and the appropriateness of continuing venlafaxine should be considered..

Among the side effects, there are changes in the parameters of liver tests, an increase in blood cholesterol, weight loss, hyponatremia, visual impairment.

liver failure; in parallel with the intake of MAO inhibitors; kidney pathology with creatinine clearance less than 10 ml per minute; the period of bearing a child; breast-feeding; childhood.

Patients recommending these drugs as a whole, adhering to all doses and treatment regimens.